|
New tools for the diagnosis of cancer and optimization of treatments against cancers
Key words: diagnostic, cancer
Consortium:
Companies: OncoMethylome Sciences (Coordinator), GlaxoSmithKline Biologicals
Research centers: ULg (Gynecology), ULg (Pathologic Cytology and anatomy),
ULg (Obstetrics and gynecology - Pathology)
Topic of the project
The goal of this project is to develop in vitro tests (I) of diagnosis of cancer and (II) of therapeutic personalization, based on the detection of methylation gene. This project mainly will make it possible to determine so some of these markers of methylation are able (I) to diagnose - and this in an early way - gynaecological cancers of the woman (in fact the breast cancer, endometer (or possibly ovary), and cervix), and (II) to provide indications making it possible to personalize a therapeutic vaccination among patients reached of lung cancers or melanomist, by classifying the responders and the non-responders with the treatment and by determining the profile of aggressiveness (forecast/risk of recurrence) of cancer. The project will combine the technology of MSP patented by WHO with simple and noninvasive techniques of sampling for these two types of tests. Moreover, tests starting from tissues samples will be also planned to predict the recurrence of these cancers.
Budget
This is a 4-year project with a total budget of M€ 4.7.
Contact
Sandra Huygen (coordinator of the project)
Email: Sandra.Huygen@oncomethylome.com
OncoMethylome Sciences S.A.
Website: http://www.oncomethylome.com
|
|
|
|